Other GLP-1 Medications Involved in Litigation The federal multidistrict litigation consolidated as MDL 3094 encompasses multiple GLP-1 receptor agonist medications beyond just Ozempic, reflecting the class-wide nature of the alleged injuries and inadequate warnings
That said, there are biologically plausible indirect pathways by which semaglutide treatmentespecially when accompanied by rapid appetite suppression, gastrointestinal adverse effects, and clinically meaningful weight losscould unmask or exacerbate pre-existing vaginal symptoms (for example, genitourinary syndrome of menopause) or contribute to discomfort through dehydration, altered sex steroid milieu, or pelvic soft-tissue volume changes
The real cost is buried in a long, convoluted disclaimer under the checkout button
At the time, members of the fitness community were starting to inject themselves with peptidesshort chains of amino acids, sometimes called microproteins, that often act as signalling molecules in the body